Monday, September 30, 2013

SANCUSO to begin marketing in the EU

This week, ProStrakan Group announced the approval to market SANCUSO(R) (Granisetron Transdermal System) in the EU. 3M Drug Delivery Systems will be manufacturing the product, which begins marketing this month. The United Kingdom, Germany, and the Netherlands are the first few countries the product will be available in, with more expected to be added to the list in 2014.

Initially introduced in the United States in 2008, SANCUSO is the first and only treatment for chemotherapy-induced nausea and vomiting that does not require pills or intravenous (IV) administration. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting. This simple-to-use treatment has been proven effective in patients at risk for chemotherapy-induced nausea and vomiting.

Will the introduction of SANCUSO open the door for transdermal delivery systems in the EU? Want to learn more about the latest in drug delivery? IIR's 18th Annual Drug Delivery Partnerships will help you form a drug delivery strategy that keeps you ahead of the market, register today!

To learn more, download our agenda. We hope to see you January 27-29 in Boca Raton!

No comments:

Post a Comment